Merck has announced the final results from its Phase III open-label study of Victrelis, used for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infection.

Victrelis is the first in a class of hepatitis C virus protease inhibitors approved by the US Food and Drug Administration for use in combination with Pegintron (peginterferon alfa-2b) and ribavirin (P/R).

The multinational open-label trial enrolled 687 treatment-naïve adult patients with chronic HCV genotype 1 who had baseline haemoglobin levels of less than or equal to 15g/dL to compare the impact of two anaemia management strategies on sustained virologic response (SVR) when treated with Victrelis in combination with P/R.

In the study, patients were treated with a four-week lead-in of peginterferon alfa-2b (1.5mcg/kg/week) and an investigational dose of ribavirin (600-1,400mg/day), followed by the addition of Victrelis at a dose of 800mg three times a day after week four for 24 or 44 weeks based on HCV-RNA levels at treatment week eight.

The trial’s primary endpoint was the comparison of SVR in patients who were randomised to receive ribavirin dose reduction or the addition of erythropoietin (EPO).

The data demonstrated that the rates of SVR were 71% for both groups; those patients whose anaemia was managed by ribavirin dose reduction and those patients whose anemia was managed by the addition of EPO. The rates of relapse were the same at 10% in both groups.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chief of hepatology and liver transplantation at Cedars-Sinai Medical Center, US, Fred Poordad said the results showed that there was no difference in SVR rates among the anaemia management strategies and that ribavirin dose reduction should be the primary strategy for managing anaemia in patients taking Victrelis combination therapy.

In the pivotal clinical trials, the proportion of patients who experienced haemoglobin values less than 10g/dL and less than 8.5g/dL was higher in subjects treated with Victrealis combination therapy compared to those treated with P/R alone, respectively.